


CLAIMS

1. A compound of Formula (I), or a stereoisomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug thereof, wherein:




Formula (I)


in the formula (I),

X is O, or NH;

Y is N or C-Z, wherein Z is -H or -CN;



R³ is -H, halogen, C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃ alkyl substituted by halogen, or C₁-C₃ alkoxy substituted by halogen;





M is O or S;

T is linear C₁-C₃ alkyl, or linear C₁-C₃ alkyl independently substituted by R⁵ and R⁶, respectively;

R⁵ and R⁶ are independently -H, halogen, C₁-C₃ alkyl, or C₁-C₃ alkyl substituted by halogen;

R⁴ is aryl, 5- to 6-membered heteroaryl, aryl substituted by 1-3 identical or different R⁷, or 5- to 6-membered heteroaryl substituted by 1-3 identical or different R⁷, wherein the heteroaryl group is a heteroaryl group containing 1-3 heteroatoms selected from N, O or S;

R⁷ is -H, halogen, amino, hydroxy, cyano, C₁-C₃ alkylthio, amino substituted with mono- or di-C₁-C₃ alkyl, C₃-C₄ cycloalkyl, unsubstituted or substituted C₁-C₆ alkyl, or unsubstituted or substituted C₁-C₆ alkoxy, wherein the substituent of the substituted C₁-C₆ alkyl is halogen, hydroxy, amino substituted with mono- or di-C₁-C₃ alkyl, or C₁-C₃ alkoxy, and wherein the substituent of the substituted C₁-C₆ alkoxy is halogen, C₁-C₃ alkoxy, or amino substituted with mono- or di-C₁-C₃ alkyl;



T₁ is linear C₁-C₈ alkyl, linear C₁-C₈ alkyl independently substituted by R⁹ and R¹⁰,

respectively;

R^9 and R^{10} are each independently -H, or C_1 - C_3 alkyl;

R^8 is -H, hydroxy, C_1 - C_3 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_3 alkoxy, C_1 - C_3 alkylthio, 4- to 7-membered heterocyclyl or $-NR^{11}R^{12}$;

5 R^{11} and R^{12} are each independently -H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_6 alkyl substituted by hydroxy, or C_1 - C_6 alkyl substituted by C_1 - C_3 alkoxy;


the 4- to 7-membered heterocyclyl is a heterocyclyl containing 1-2 heteroatoms selected from N, O or S, the heterocyclyl is unsubstituted or substituted by one or two of the group consisting of: C_1 - C_3 alkyl, aldehyde group, C_1 - C_4 alkylacyl, aminoacyl, aminoacyl wherein the
10 amino is substituted with mono- or di- C_1 - C_3 alkyl, C_1 - C_3 alkylsulfonyl, and C_1 - C_3 alkylsulfinyl, or the sulfur in the heterocycle is oxidized by one to two oxygen atoms.

2. The compound of Formula (I), according to claim 1 wherein;


in the formula (I),

15 X is NH;

Y is N;



R^3 is -H, halogen, C_1 - C_3 alkyl, or C_1 - C_3 alkyl substituted by halogen;





20 M is O or S;

T is linear C_1 - C_3 alkyl;

R^4 is aryl, 5- to 6-membered heteroaryl, or aryl substituted by 1-3 identical or different R^7 , wherein the heteroaryl group is a heteroaryl group containing 1-3 heteroatoms selected from N, O or S;

25 R^7 is -H, or halogen;




T_1 is linear C_1 - C_8 alkyl;


R^8 is $-NR^{11}R^{12}$; and

30 R^{11} and R^{12} are each independently -H, C_1 - C_6 alkyl, or C_3 - C_6 cycloalkyl.

3. The compound, or stereoisomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug thereof according to claim 1, wherein:



R^3 is -H, fluorine, chlorine, bromine, methyl, ethyl, methoxy, ethoxy, trifluoromethyl or trifluoromethoxy;



M is O or S,



T is linear C_1 - C_2 alkyl, or linear C_1 - C_2 alkyl independently substituted by R^5 and R^6 , respectively;

R^5 and R^6 are independently is -H, -F, methyl, ethyl or trifluoromethyl;

R^4 is aryl, 5- to 6-membered heteroaryl, aryl substituted by 1-2 identical or different R^7 , or 5- to 6-membered heteroaryl substituted by 1-2 identical or different R^7 , wherein the aryl or heteroaryl group is selected from the group consisting of: phenyl, pyridyl, pyrimidinyl, thiazolyl, thienyl, pyrrolyl, thiadiazolyl, furyl, oxazolyl or isoxazolyl; and

R^7 is -H, -F, -Cl, -Br, -CF₃, -OCF₃, amino, hydroxy, cyano, methylthio, ethylthio, propylthio, isopropylthio, methylamino, ethylamino, dimethylamino, diethylamino, cyclopropyl, cyclobutyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, methylaminomethyl, methylaminoethyl, methylaminopropyl, dimethylaminomethyl, dimethylaminoethyl, dimethylaminopropyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, methoxyethoxy, methoxypropoxy, ethoxyethoxy, ethoxypropoxy, methylaminoethoxy, methylaminopropoxy, ethylaminoethoxy, ethylaminopropoxy, dimethylaminoethoxy, dimethylaminopropoxy, diethylaminoethoxy, or diethylaminopropoxy.

4. The compound, or stereoisomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug thereof according to claim 1 or 3, wherein:



T_1 is linear C_1 - C_6 alkyl, or linear C_1 - C_6 alkyl independently substituted by R^9 and R^{10} , respectively;

R^9 and R^{10} are independently -H or methyl;


R^8 is -H, hydroxy, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl,

cyclohexyl, methoxy, ethoxy, propoxy, isopropoxy, methylthio, ethylthio, propylthio, isopropylthio, 5- to 6-membered heterocyclyl or -NR¹¹R¹²,



R¹¹ and R¹² are each independently -H, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, sec-butyl, 1-ethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, methoxyhexyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, ethoxyhexyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, propoxyhexyl, isopropoxyethyl, isopropoxypropyl, isopropoxybutyl, isopropoxypentyl or isopropoxyhexyl;

the 5- to 6-membered heterocyclyl is a heterocyclyl containing 1-2 heteroatoms selected from N, O or S, the 5- to 6-membered heterocyclyl is unsubstituted or substituted by one or two of the group consisting of: methyl, ethyl, propyl, isopropyl, aldehyde group, formyl, acetyl, propionyl, butyryl, isobutyryl, aminoacyl, methylaminoacyl, dimethylaminoacyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, methylsulfinyl, ethylsulfinyl, or isopropylsulfinyl, or sulfur in the heterocycle is oxidized by one to two oxygen atoms;

the 5- to 6-membered heterocycle is selected from:



5. The compound, or stereoisomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug thereof according to any one of claims 1, 3 or 4, wherein:



T₁ is linear C₁-C₆ alkyl, or linear C₁-C₆ alkyl independently substituted by R⁹ and R¹⁰, respectively;

R⁹ and R¹⁰ are each independently -H or methyl;


R⁸ is -H, hydroxy, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, methylthio, ethylthio, propylthio, isopropylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 5- to 6-membered heterocyclyl or -NR¹¹R¹²,

R¹¹ and R¹² are each independently -H, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, sec-butyl, 1-ethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, isopropoxyethyl, isopropoxypropyl,

isopropoxybutyl or isopropoxypentyl;


the 5- to 6-membered heterocyclyl is a heterocyclyl containing 1-2 heteroatoms selected from N, O or S, the 5- to 6-membered heterocyclyl is unsubstituted or substituted by one or two of the group consisting of: methyl, ethyl, propyl, isopropyl, aldehyde group, formyl, acetyl, propionyl, butyryl, isobutyryl, aminoacyl, methylaminoacyl, dimethylaminoacyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, methylsulfinyl, ethylsulfinyl, or isopropylsulfinyl, or the sulfur in the heterocycle is oxidized by one to two oxygen atoms;

the 5- to 6-membered heterocyclyl is selected from:



R^{13} is -H, amino, methylamino, dimethylamino, methyl, ethyl, propyl, or isopropyl.

6. A compound of Formula (I), or a stereoisomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug thereof, wherein:




Formula (I)


in the formula (I),

X is O, or NH;

Y is N or C-Z, wherein Z is -H or -CN;



R^3 is -H, halogen, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, C_1 - C_3 alkyl substituted by halogen or C_1 - C_3 alkoxy substituted by halogen;



M is O or S;



T is linear C_1 - C_3 alkyl, or linear C_1 - C_3 alkyl independently substituted by R^5 and R^6 , respectively;

R^5 and R^6 are each -H, halogen, C_1 - C_3 alkyl, or C_1 - C_3 alkyl substituted by halogen;

R^4 is substituted or unsubstituted fused heteroaryl, the substituted fused heteroaryl is

substituted by 1-3 identical or different R^7 , the fused ring heteroaryl group is a heteroaryl group containing 1-3 heteroatoms selected from N, O or S;

R^7 is -H, halogen, amino, hydroxy, cyano, C_1 - C_3 alkylthio, amino substituted with mono- or di- C_1 - C_3 alkyl, C_3 - C_4 cycloalkyl, unsubstituted or substituted C_1 - C_6 alkyl, or unsubstituted or substituted C_1 - C_6 alkoxy, wherein the substituent of the substituted C_1 - C_6 alkyl is halogen, hydroxy, amino substituted with mono- or di- C_1 - C_3 alkyl, or C_1 - C_3 alkoxy, and wherein the substituent of the substituted C_1 - C_6 alkoxy is halogen, C_1 - C_3 alkoxy, or amino substituted with mono- or di- C_1 - C_3 alkyl;



T_1 is linear C_1 - C_8 alkyl, or linear C_1 - C_8 alkyl independently substituted by R^9 and R^{10} , respectively;

R^9 and R^{10} are each independently -H, or C_1 - C_3 alkyl;

R^8 is -H, hydroxy, C_1 - C_3 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_3 alkoxy, C_1 - C_3 alkylthio, 4- to 7-membered heterocyclyl or $-NR^{11}R^{12}$;


R^{11} and R^{12} are each independently -H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_6 alkyl substituted by hydroxy or C_1 - C_6 alkyl substituted by C_1 - C_3 alkoxy; and

the 4- to 7-membered heterocyclyl is a heterocyclyl containing 1-2 heteroatoms selected from N, O or S, the heterocyclyl is unsubstituted or substituted by any one or two of the group consisting of: C_1 - C_3 alkyl, aldehyde group, C_1 - C_4 alkylacyl, aminoacyl, aminoacyl wherein the amino is substituted with mono- or di- C_1 - C_3 alkyl, C_1 - C_3 alkylsulfonyl, C_1 - C_3 alkylsulfinyl, hydroxy, halogen, C_1 - C_3 hydroxyalkyl, or C_1 - C_3 haloalkyl, or the sulfur in the heterocycle is oxidized by one to two oxygen atoms.


7. The compound of Formula (I), according to claim 6 wherein;
in the formula (I),

X is NH;

Y is N;





R^3 is -H, halogen, C_1 - C_3 alkyl, or C_1 - C_3 alkyl substituted by halogen;





M is O or S;

T is linear C₁-C₃ alkyl;

R⁴ is substituted or unsubstituted fused heteroaryl, wherein the fused ring heteroaryl group is a heteroaryl group containing 1-3 heteroatoms selected from N, O or S;

R² is  or ,


5 L₁ is selected from:  or .

T₁ is linear C₁-C₈ alkyl;



R⁸ is -NR¹¹R¹²; and

R¹¹ and R¹² are each independently -H, or C₁-C₆ alkyl.

10 8. The compound, or stereoisomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug thereof according to claim 6, wherein:




R³ is -H, fluorine, chlorine, bromine, methyl, ethyl, methoxy, ethoxy, trifluoromethyl or trifluoromethoxy;

15 L is  or .

M is O or S;

T is linear C₁-C₂ alkyl, or linear C₁-C₂ alkyl independently substituted by R⁵ and R⁶, respectively;

R⁵ and R⁶ are each independently -H, -F, methyl, ethyl or trifluoromethyl;


20 R⁴ is unsubstituted or substituted , the group is substituted by 1-3 identical or different R⁷,

R⁷ is -H, -F, -Cl, -Br, -CF₃, -OCF₃, amino, hydroxy, cyano, methylthio, ethylthio, propylthio, isopropylthio, methylamino, ethylamino, dimethylamino, diethylamino, cyclopropyl, cyclobutyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, methylaminomethyl, methylaminoethyl, methylaminopropyl, dimethylaminomethyl, dimethylaminoethyl, dimethylaminopropyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, methoxyethoxy, methoxypropoxy, ethoxyethoxy, ethoxypropoxy, methylaminoethoxy, methylaminopropoxy, ethylaminoethoxy, ethylaminopropoxy, dimethylaminoethoxy, dimethylaminopropoxy, diethylaminoethoxy, or diethylaminopropoxy.

25

30

9. A compound of Formula (I), or a stereoisomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug thereof, wherein:




Formula (I)


5 in the formula (I),

X is O, or NH;

Y is N or C-Z, wherein Z is -H or -CN;



10 R³ is -H, halogen, C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃ alkyl substituted by halogen or C₁-C₃ alkoxy substituted by halogen;





M is O or S;

T is linear C₁-C₃ alkyl, or linear C₁-C₃ alkyl independently substituted by R⁵ and R⁶, respectively;

15 R⁵ and R⁶ are each independently -H, halogen, C₁-C₃ alkyl, or C₁-C₃ alkyl substituted by halogen;

R⁴ is aryl, 5- to 6-membered heteroaryl, aryl substituted by 1-3 identical or different R⁷, or 5- to 6-membered heteroaryl substituted by 1-3 identical or different R⁷, wherein the heteroaryl group is a heteroaryl group containing 1-3 heteroatoms selected from N, O or S;

20 R⁷ is -H, halogen, amino, hydroxy, cyano, C₁-C₃ alkylthio, amino substituted with mono- or di-C₁-C₃ alkyl, C₃-C₄ cycloalkyl, unsubstituted or substituted C₁-C₆ alkyl, or unsubstituted or substituted C₁-C₆ alkoxy, wherein the substituent of the substituted C₁-C₆ alkyl is halogen, hydroxy, amino substituted with mono- or di-C₁-C₃ alkyl, or C₁-C₃ alkoxy, and wherein the substituent of the substituted C₁-C₆ alkoxy is halogen, C₁-C₃ alkoxy, or amino substituted with
25 mono- or di-C₁-C₃ alkyl;



T₁ is linear C₁-C₈ alkyl, or linear C₁-C₈ alkyl independently substituted by R⁹ and R¹⁰, respectively;

R⁹ and R¹⁰ are each independently -H, or C₁-C₃ alkyl;

R⁸ is -H, hydroxy, C₁-C₃ alkyl, C₃-C₇ cycloalkyl, C₁-C₃ alkoxy, C₁-C₃ alkylthio, 4- to 7-membered heterocyclyl or -NR¹¹R¹²;

R¹¹ and R¹² are each independently -H, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkyl substituted by hydroxyl or C₁-C₆ alkyl substituted by C₁-C₃ alkoxy; and

the 4- to 7-membered heterocyclyl is a heterocyclyl containing 1-2 heteroatoms selected from N, O or S, the heterocyclyl is unsubstituted or substituted by any one or two of the group consisting of: C₁-C₃ alkyl, hydroxy, halogen, C₁-C₃ hydroxyalkyl, or C₁-C₃ haloalkyl.

10 10. The compound, or stereoisomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug thereof according to any one of claims 1-9, wherein the compound is selected from the group consisting of:

1-(10-((4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

15 1-(10-((4-phenoxyphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

1-(10-((3-chloro-4-((3-fluorobenzyloxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

20 1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

1-(10-((4-(m-tolyloxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

1-(10-((4-(3-chlorophenoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

25 1-(10-((4-(3-fluorophenoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

1-(10-((4-(2-fluorophenoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

30 1-(10-((4-(4-fluorophenoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

1-(10-((4-(4-chlorophenoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

1-(10-((4-(2-methoxyphenoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

35 1-(10-((4-(pyridin-2-yloxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-

f]quinazolin-4-yl)prop-2-en-1-one;
1-(10-((4-(pyridin-3-yloxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-
f]quinazolin-4-yl)prop-2-en-1-one;
1-(10-((4-(3-methoxyphenoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-
5 f]quinazolin-4-yl)prop-2-en-1-one;
1-(10-((4-(thiazol-2-yloxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-
f]quinazolin-4-yl)prop-2-en-1-one;
1-(10-((3-fluoro-4-phenoxyphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-
f]quinazolin-4-yl)prop-2-en-1-one;
10 1-(10-((3-chloro-4-phenoxyphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-
f]quinazolin-4-yl)prop-2-en-1-one;
1-(10-((4-((4-fluorobenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-
f]quinazolin-4-yl)prop-2-en-1-one;
1-(10-((4-((3-fluorobenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-
15 f]quinazolin-4-yl)prop-2-en-1-one;
1-(10-((4-((3-trifluoromethylbenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-
[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;
1-(10-((4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-
f]quinazolin-4-yl)prop-2-en-1-one;
20 1-(10-((4-(thiophen-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-
f]quinazolin-4-yl)prop-2-en-1-one;
1-(10-((4-(thiazol-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-
f]quinazolin-4-yl)prop-2-en-1-one;
1-(10-((4-(benzylthio)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-
25 yl)prop-2-en-1-one;
1-(10-((4-((3-fluorobenzyl)oxy)-3-(trifluoromethyl)phenyl)amino)-2,3-dihydro-4H-
[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;
1-(10-((4-((3-fluorobenzyl)oxy)-3-(methoxy)phenyl)amino)-2,3-dihydro-4H-
[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;
30 1-(10-((4-((3-fluorobenzyl)oxy)-3-fluorophenyl)amino)-2,3-dihydro-4H-
[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;
1-(10-((4-((4-fluorophenyl)thio)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-
f]quinazolin-4-yl)prop-2-en-1-one;
1-(10-((2-fluoro-4-phenoxyphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-
35 f]quinazolin-4-yl)prop-2-en-1-one;

1-(10-((4-(2-(2-(dimethylamino)ethoxy)phenoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

1-(10-((4-(2-(3-(dimethylamino)propoxy)phenoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

5 1-(10-((4-(2-(2-methoxyethoxy)phenoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

1-(10-(4-phenoxyphenoxy)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

10 1-(10-(3-chloro-4-(pyridin-2-ylmethoxy)phenoxy)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

1-(10-(3-chloro-4-((3-fluorobenzyl)oxy)phenoxy)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

1-(10-(4-(4-chlorophenoxy)phenoxy)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

15 1-(10-(4-(4-fluorophenoxy)phenoxy)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

1-(10-(4-(2,5-dichlorophenoxy)phenoxy)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

20 1-(10-(4-(pyridin-2-ylmethoxy)phenoxy)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

1-(10-(4-((2-fluorobenzyl)oxy)phenoxy)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

1-(10-(4-((3-fluorobenzyl)oxy)phenoxy)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

25 1-(10-(4-((4-fluorobenzyl)oxy)phenoxy)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)prop-2-en-1-one;

(E)-4-(dimethylamino)-1-(10-((4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

30 (E)-4-(dimethylamino)-1-(10-((4-phenoxyphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-1-(10-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(dimethylamino)but-2-en-1-one;

(E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(dimethylamino)but-2-en-1-one;

35 (E)-4-(dimethylamino)-1-(10-((4-(m-tolyloxy)phenyl)amino)-2,3-dihydro-4H-

[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;
 (E)-4-(dimethylamino)-1-(10-((4-(3-chlorophenoxy)phenyl)amino)-2,3-dihydro-4H-
 [1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;
 (E)-4-(dimethylamino)-1-(10-((4-(3-fluorophenoxy)phenyl)amino)-2,3-dihydro-4H-
 5 [1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;
 (E)-4-(dimethylamino)-1-(10-((4-(2-fluorophenoxy)phenyl)amino)-2,3-dihydro-4H-
 [1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;
 (E)-4-(dimethylamino)-1-(10-((4-(4-fluorophenoxy)phenyl)amino)-2,3-dihydro-4H-
 [1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;
 10 (E)-4-(dimethylamino)-1-(10-((4-(4-chlorophenoxy)phenyl)amino)-2,3-dihydro-4H-
 [1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;
 (E)-4-(dimethylamino)-1-(10-((4-(2-methoxyphenoxy)phenyl)amino)-2,3-dihydro-4H-
 [1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;
 (E)-4-(dimethylamino)-1-(10-((4-(pyridin-2-yloxy)phenyl)amino)-2,3-dihydro-4H-
 15 [1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;
 (E)-4-(dimethylamino)-1-(10-((4-(pyridin-3-yloxy)phenyl)amino)-2,3-dihydro-4H-
 [1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;
 (E)-4-(dimethylamino)-1-(10-((4-(3-methoxyphenoxy)phenyl)amino)-2,3-dihydro-4H-
 [1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;
 20 (E)-4-(dimethylamino)-1-(10-((4-(thiazol-2-yloxy)phenyl)amino)-2,3-dihydro-4H-
 [1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;
 (E)-4-(dimethylamino)-1-(10-((3-fluoro-4-phenoxyphenyl)amino)-2,3-dihydro-4H-
 [1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;
 (E)-4-(dimethylamino)-1-(10-((3-chloro-4-phenoxyphenyl)amino)-2,3-dihydro-4H-
 25 [1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;
 (E)-4-(dimethylamino)-1-(10-((4-((4-fluorobenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-
 [1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;
 (E)-4-(dimethylamino)-1-(10-((4-((3-fluorobenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-
 [1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;
 30 (E)-4-(dimethylamino)-1-(10-((4-((3-(trifluoromethylbenzyl)oxy)phenyl)amino)-2,3-
 dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;
 (E)-4-(dimethylamino)-1-(10-((4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-
 [1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;
 (E)-4-(dimethylamino)-1-(10-((4-(thiophen-2-ylmethoxy)phenyl)amino)-2,3-dihydro-
 35 4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-4-(dimethylamino)-1-(10-((4-(thiazol-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-4-(dimethylamino)-1-(10-((4-(benzylthio)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

5 (E)-4-(dimethylamino)-1-(10-((4-((3-fluorobenzyl)oxy)-3-(trifluoromethyl)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-4-(dimethylamino)-1-(10-((4-((3-fluorobenzyl)oxy)-3-methoxyphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

10 (E)-4-(dimethylamino)-1-(10-((4-((3-fluorobenzyl)oxy)-3-fluorophenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-4-(dimethylamino)-1-(10-((4-((4-fluorophenyl)thio)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

15 (E)-4-(dimethylamino)-1-(10-((4-(2-fluoro-5-methylphenoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-4-(dimethylamino)-1-(10-((4-(5-chloro-2-fluorophenoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-4-(dimethylamino)-1-(10-((4-(2,5-difluorophenoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

20 (E)-4-(dimethylamino)-1-(10-((4-(1-(3-fluorophenyl)ethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-4-(dimethylamino)-1-(10-((4-(1-(pyridin-2-yl)ethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

25 (E)-4-(dimethylamino)-1-(10-((4-(pyridin-3-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-4-(dimethylamino)-1-(10-((4-(pyridin-4-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-1-(10-((4-(benzyloxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(dimethylamino)but-2-en-1-one;

30 (E)-4-(dimethylamino)-1-(10-((4-((2-fluorobenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-4-(dimethylamino)-1-(10-((4-((2-chlorobenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

35 (E)-4-(dimethylamino)-1-(10-((4-((2-methylbenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-4-(dimethylamino)-1-(10-((4-((2-methoxybenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-1-(10-((4-((3-chlorobenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(dimethylamino)but-2-en-1-one;

5 (E)-4-(dimethylamino)-1-(10-((4-((3-methylbenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-4-(dimethylamino)-1-(10-((4-((3-cyanobenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

10 (E)-4-(dimethylamino)-1-(10-((4-((3-methoxybenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-4-(dimethylamino)-1-(10-((4-((4-chlorobenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-4-(dimethylamino)-1-(10-((4-((4-methylbenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

15 (E)-1-(10-((4-((2,5-difluorobenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(dimethylamino)but-2-en-1-one;

(E)-1-(10-((4-((2-chloro-5-fluorobenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(dimethylamino)but-2-en-1-one;

20 (E)-1-(10-((4-phenoxyphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(pyrrolidin-1-yl)but-2-en-1-one;

(E)-4-(diethylamino)-1-(10-((4-phenoxyphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-1-(10-((4-phenoxyphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(piperidin-1-yl)but-2-en-1-one;

25 (E)-4-morpholino-1-(10-((4-phenoxyphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

(E)-4-(4-methylpiperazin-1-yl)-1-(10-((4-phenoxyphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

30 (E)-1-(10-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-morpholinobut-2-en-1-one;

(E)-1-(10-((2-fluoro-4-phenoxyphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(piperidin-1-yl)but-2-en-1-one;

(E)-1-(10-((3-fluoro-4-phenoxyphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(piperidin-1-yl)but-2-en-1-one;

35 (E)-1-(10-((4-(2-fluorophenoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-

f]quinazolin-4-yl)-4-((4-methoxybutyl)amino)but-2-en-1-one;

(E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(cyclopropyl(methyl)amino)but-2-en-1-one;

5 (E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(cyclopropylamino)but-2-en-1-one;

(E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(isopropylamino)but-2-en-1-one;

(E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-morpholinobut-2-en-1-one;

10 (E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(4-methylpiperazin-1-yl)but-2-en-1-one;

(E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(diethylamino)but-2-en-1-one;

15 (E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(pyrrolidin-1-yl)but-2-en-1-one;

(E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(piperidin-1-yl)but-2-en-1-one;

(E)-4-(4-acetylpiperazin-1-yl)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-en-1-one;

20 (E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(cyclobutylamino)but-2-en-1-one;

(E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(cyclobutyl(methyl)amino)but-2-en-1-one;

25 (E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(isopropyl(methyl)amino)but-2-en-1-one;

(S,E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-3-(1-methylpyrrolidin-2-yl)prop-2-en-1-one;

1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)but-2-yne-1-one;

30 (R,E)-1-(10-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-3-(1-methylpyrrolidin-2-yl)prop-2-en-1-one;

(E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(4-hydroxypiperidin-1-yl)but-2-en-1-one;

35 (E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(4-hydroxyl-4-methylpiperidin-1-yl)but-2-en-1-one;

(E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(4-(hydroxymethyl)piperidin-1-yl)but-2-en-1-one;

(E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(4-fluoropiperidin-1-yl)but-2-en-1-one;

5 (E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-((2-methoxyethyl)(methyl)amino)but-2-en-1-one;

(E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-((3-hydroxypropyl)(methyl)amino)but-2-en-1-one;

(S,E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(2,4-dimethylpiperazin-1-yl)but-2-en-1-one;

10 (E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-((2-hydroxyethyl)(methyl)amino)but-2-en-1-one;

(R,E)-1-(10-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(2,4-dimethylpiperazin-1-yl)but-2-en-1-one;

15 (E)-1-(10-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(dimethylamino)but-2-en-1-one;

(E)-1-(10-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-chlorophenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(dimethylamino)but-2-en-1-one;

(E)-1-(10-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-chlorophenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(4-methylpiperazin-1-yl)but-2-en-1-one;

20 (E)-1-(10-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-chlorophenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(isopropyl(methyl)amino)but-2-en-1-one;

(E)-1-(10-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-chlorophenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(piperidin-1-yl)but-2-en-1-one;

25 (E)-1-(10-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-chlorophenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(cyclobutyl(methyl)amino)but-2-en-1-one;

(E)-1-(10-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-chlorophenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-((2-methoxyethyl)(methyl)amino)but-2-en-1-one;

30 (E)-1-(10-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-chlorophenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(diethylamino)but-2-en-1-one;

(E)-1-(10-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(4-methylpiperazin-1-yl)but-2-en-1-one;

(E)-1-(10-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(isopropyl(methyl)amino)but-2-en-1-one;

35

(E)-1-(10-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(piperidin-1-yl)but-2-en-1-one;

(E)-1-(10-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(cyclobutyl(methyl)amino)but-2-en-1-one;


5 (E)-1-(10-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-((2-methoxyethyl)(methyl)amino)but-2-en-1-one; and

(E)-1-(10-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-4-(diethylamino)but-2-en-1-one.

10


11. A method for preparing the compound according to any one of claims 1-10, characterized in that it comprises the following steps,

the compound represented by formula (I) is prepared by the reaction of $R^2C(O)Cl$ with the compound represented by formula (VIII) or by the chlorinating reaction of R^2COOH followed
15 by the reaction with the compound represented by formula (VIII);



or, when R^2 is $\text{---}L_1-T_1-R^8$, wherein L_1 is $\text{---}\text{CH=CH}\text{---}$, and R^8 is $-NR^{11}R^{12}$, the compound represented by formula (I) is prepared by reacting the compound represented by


formula (VIII) with $\text{O=C(Cl)-CH=CH-T}_1\text{---Br}$ and $\text{HNR}^{11}\text{R}^{12}$,



20


or, when R^2 is $\text{---}L_1-R^8$ or $\text{---}L_1-T_1-R^8$, wherein L_1 is $\text{---}\text{CH=CH}\text{---}$, the compound represented by formula (I) is prepared by reacting the compound represented by

formula (IX) with $\text{OHC---}R^8$ or $\text{OHC---}T_1\text{---}R^8$,



$\text{R}^1, \text{R}^2, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{X}, \text{Y}, \text{L}_1$ and T_1 are as defined in any one of claims 1-9.


12. A compound represented by formula (VIII),



wherein R^1, X and Y are as defined in any one of claims 1-9.


13. A method for preparing the compound of claim 12, characterized in that X and R^1 are as defined in any one of claims 1-9, and Y is N , and the preparation method thereof comprises the following steps:

method A:



2,3,4,9-tetrahydro-10H-[1,4]oxazino[2,3-f]quinazolin-10-one represented by formula (V), and R^1XH are fully contacted with Castros reagent to afford the compound represented by formula (VIII);


or method B:



2,3,4,9-tetrahydro-10H-[1,4]oxazino[2,3-f]quinazolin-10-one represented by formula (V) is fully contacted with Castros reagent to afford the compound represented by formula (VI),

and compound of formula (VI) is further reacted with R^1XH to afford the compound represented by formula (VIII);

or method C:




the compound represented by formula (II) is reacted with a chlorinating reagent and then reacted with R^1XH to afford the compound represented by formula (VII), and the compound represented by formula (VII) is further subjected to reduction cyclization reaction to afford the compound represented by formula (VIII).

14. The compound of formula (I) according to any one of claims 1-10, or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein, the pharmaceutically acceptable salt of the compound is selected from one or more of the following salts of the said compound: hydrochloride, hydrobromide, hydroiodide, perchlorate, sulfate, nitrate, phosphate, formate, acetate, propionate, glycolate, lactate, succinate, maleate, tartrate, malate, citrate, fumarate, gluconate, benzoate, mandelate, methanesulfonate, isethionate, benzenesulfonate, oxalate, palmitate, 2-naphthalenesulfonate, p-toluenesulfonate, cyclohexylsulfamate, salicylate, hexonate, trifluoroacetate, aluminum salt, calcium salt, chloroprocaine salt, choline salt, diethanolamine salt, ethylenediamine salt, lithium salt, magnesium salt, potassium salt, sodium salt and zinc salt.

15. A pharmaceutical composition for treating diseases related to tyrosine kinases EGFR, HER2, HER3 and HER4, which comprises the compound of formula (I) or a pharmaceutically acceptable salt or hydrate or solvate or prodrug thereof according to any one of claims 1-10 and one or more pharmaceutically acceptable carrier(s) or excipient(s).

16. A pharmaceutical composition comprising the compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof according to any one of claims 1-10 as an active ingredient, one or more other therapeutic agents, and one or more pharmaceutically acceptable carriers or excipients.

17. A compound having the following structure:



18. A method of preparing the compound of claim 17, which comprises the following

5 steps:

